I5NP

DRUG2 trials

Sponsors

Quark Pharmaceuticals

Conditions

Acute Kidney InjuryAcute Renal FailureDelayed Graft FunctionOther Complication of Kidney Transplant

Phase 1

A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)

TerminatedNCT00683553

Quark PharmaceuticalsAcute Kidney Injury, Acute Renal Failure

Start: 2008-05-31End: 2010-09-30Updated: 2010-11-16

I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation

CompletedNCT00802347

Quark PharmaceuticalsDelayed Graft Function, Other Complication of Kidney Transplant

Start: 2008-12-31End: 2014-05-31Updated: 2014-09-18

Related Papers

Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study

Circulation2021-09-0390 citations